Interactions between agenerase(amprenavir) and Cordarone (amiodarone)
amiodarone and amprenavir (Major Drug-Drug)
MONITOR CLOSELY: Coadministration with amprenavir or its prodrug, fosamprenavir, may significantly increase the plasma concentrations of amiodarone, systemic lidocaine, and quinidine. The proposed mechanism is amprenavir inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of these antiarrhythmic agents. The interaction has not been studied but could conceivably lead to serious and/or life-threatening reactions including cardiac arrhythmias and other toxicities.
MANAGEMENT: Caution is advised if amprenavir or fosamprenavir must be used with amiodarone, systemic lidocaine, or quinidine. Pharmacologic response and plasma antiarrhythmic drug levels should be monitored more closely whenever amprenavir or fosamprenavir is added to or withdrawn from therapy, and the antiarrhythmic dosage adjusted as necessary.